trial
as of 2026-07-01NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCTId NCT06963034
at a glance
Phase 3 · Recruiting
Enrollment 284 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2027-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Recruiting
Enrollment
284 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-05-08
Primary completion
2027-10
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
21 total
Bryant, United StatesLittle Rock, United StatesAnaheim, United StatesPico Rivera, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United StatesHollywood, United StatesMiami Lakes, United StatesAtlanta, United StatesDecatur, United StatesSnellville, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
284
Phase
PHASE3
Primary Completion Date
2027-10
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator